malarial

Conessine (Conessinum), a steroidal alkaloid isolated from Holarrhena floribunda, interacts with the histamine H3 receptor and has anti-malarial activity.

Quinine dihydrochloride (Quinine bimuriate) is a primary alkaloid of various species of Cinchona (Rubiaceae). It is also an antimalarial and muscle relaxant (skeletal).

Quinine hydrochloride dihydrate (Quinine HCl Dihydrate) is a white crystalline K+ channel blocker, used to treat malaria.

Tafenoquine (WR 238605) is an antimalarial prophylactic agent with schizonticidal activity, useful in hemolytic anemia research.

Tafenoquine Succinate (WR 238605 (Succinate)) is an 8-aminoquinoline. and is an agent of anti-malarial prophylactic.

Ascomycin (Immunomycin)(Immunomycin, FR-900520, FK520) is an ethyl analog of tacrolimus (FK506) with strong immunosuppressant properties.

Lupeol (Monogynol B) is a novel androgen receptor inhibitor with anti-inflammatory and antioxidant activity.

Tectol has anti-plasmodial activity, it as a moderately active growth inhibitor with an IC50 3.44±0.20μM. It exhibited significant activity against human leukemia cell lines HL60 and CEM. Tectol may cause itchy dermatitis, the dermatitis appeared on the n

Antimalarial agent 30 has anti-Plasmodium berghei liver stage parasite activity and antimalarial activity for the study of malarial infections.

Antimalarial agent 14 (NSC-102533) is a bioactive chemical.

Antimalarial agent 13 (N2-(3-chlorophenyl)-N4-(furan-2-ylmethyl)quinazoline-2,4-diamine) is a potent antimalarial agent.

Antimalarial agent 1 is an effective antimalarial agent.

Compound 42 (Compound 2), an antimalarial agent, effectively inhibits Plasmodium falciparum during the asexual blood stages (IC 50 <0.5μM) and gametocytes (IC 50 is 0.14 μM).

Antimalarial agent 43 (compound 16c) is an antimalarial compound that exhibits an IC50 value of 0.0151 μM against the 3D7 strain.

Antimalarial agent 45 (compound 8I) is an antimalarial with activity against Plasmodium parasites, exhibiting an IC50 of 0.21 μM. It is used in the study of malaria.

Antimalarial agent 44 (Compound 3) is an antiparasitic agent effective against malaria. It exhibits good permeability in MDCK-MDR1 cell monolayers and has a high clearance rate in mouse liver microsomes.

Antimalarial agent 46 (Compound 42a) is a compound with antimalarial activity, effective in inhibiting P. falciparum lines.

Antimalarial agent 47 (compound F14) is a chemical compound effective against Plasmodium falciparum, specifically targeting the W2 strain with an IC50 value of 235 nM.

Antimalarial agent 48 (Compound 15a) is a triazine compound with antimalarial activity, showing effectiveness against Plasmodium falciparum K1 and Plasmodium falciparum FCR3 with IC50 values of 280 and 290 nM, respectively. It holds promise for research in the field of anti-infective treatments.

Antimalarial agent 49 is an oral compound with antimalarial properties. It inhibits the growth of Pf3D7 and PfK1 strains, with IC50 values of 0.84 μM and 0.4 μM, respectively. Additionally, it demonstrates the ability to suppress the liver stage development of P. berghei and can be utilized in malaria infection research.

Antimalarial agent 34 is a PfARK1/3 inhibitor, demonstrating potent antiplasmodial activity with an EC50 of 0.16 μM.

Antimalarial agent 35 is a selective inhibitor of FP2. It exhibits antimalarial activity and can act synergistically when used in combination with chloroquine.

Antimalarial agent 41 (Compound 17) exhibits antimalarial activity by inhibiting the malaria parasite Plasmodium falciparum, with IC50 values of 40 nM for NF54 strain and 76 nM for K1 strain. This compound acts as an inhibitor of P. falciparum phosphatidylinositol-4-kinase β (PfPI4K) and hERG channels, with IC50 values of 53 nM and 3 μM, respectively. Additionally, Antimalarial agent 41 shows cytotoxicity against CHO cells, with an IC50 of 34 μM. It can improve malaria infections and demonstrates favorable pharmacokinetic properties in mouse models.

Antimalarial agent 51 (Compound 2) is an orally active antimalarial compound that inhibits the growth of Plasmodium parasites by blocking nutrient uptake through the Plasmodium Surface Anion Channel (PSAC). This agent significantly restricts parasite growth under nutrient-limiting conditions and demonstrates enhanced effectiveness in combination with the residual transport inhibitor PRT-2. It is suitable for research on PSAC-targeting malaria.